Vidarbha News

Chronic Hepatitis B Virus Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Chronic Hepatitis B Virus Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

March 07
19:28 2023
Chronic Hepatitis B Virus Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Chronic Hepatitis B Virus pipeline constitutes 50+ key companies continuously working towards developing 55+ Chronic Hepatitis B Virus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Chronic Hepatitis B Virus Overview

Hepatitis B virus is a small DNA virus that belongs to the “Hepadnaviridae” family. It is a vaccine-preventable liver infection caused by the HBV. A hepatitis B infection can result in either an acute infection or a chronic infection. When a person is first infected with the hepatitis B virus, it is called an “acute infection” and most healthy adults that are infected do not have any symptoms and are able to get rid of the virus without any problems.

 

Chronic Hepatitis B Virus Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Hepatitis B Virus Market.

 

The Chronic Hepatitis B Virus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Chronic Hepatitis B Virus Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Chronic Hepatitis B Virus treatment therapies with a considerable amount of success over the years. Chronic Hepatitis B Virus Key players such as – Precision Biosciences, Silverback Therapeutics, Vir Biotechnology, Arbutus bio, Dicerna Pharmaceuticals, Roche, Ligand Pharmaceuticals, and others, are developing therapies for the Chronic Hepatitis B Virus treatment 
  • Chronic Hepatitis B Virus Emerging therapies such as – PBGENE-HBV, SBT8230, VIR-3434, AB 729, RG6346, RG7854, Pradefovir, and others are expected to have a significant impact on the Chronic Hepatitis B Virus market in the coming years. 
  • In January 2022, In a second Phase 2a/2b clinical research examining VBI-2601 (BRII-179), an immunotherapeutic candidate that targets chronic hepatitis B virus, VBI Vaccines reported that the first patient had received a dose (HBV)
  • In March 2022, ALG-020572’s development in individuals with chronic hepatitis B was stopped by Aligos Therapeutics (CHB). Once one of the patients experienced a major adverse event (SAE) that necessitated a brief hospitalisation, the first CHB group of Study ALG-020572-401 was discontinued. After receiving 210 mg of the medication several times, the patient’s alanine aminotransferase (ALT) level significantly increased. Only one of four chronic hepatitis B (CHB) participants in the sample had the potentially drug-related ALT flares, a sign of liver damage, according to Aligos.
  • In March 2021, Dicerna Pharmaceuticals announced that Roche initiated RG6346 in a Roche sponsored Phase II combination trial for the treatment of chronic hepatitis B virus (HBV) infection. The Phase II platform trial will evaluate the efficacy and safety of RG6346 in combination with multiple additional agents with different mechanisms of action. Dicerna earned a $25 million milestone in connection with the initiation of RG6346 in the Phase II combination trial

 

Route of Administration

Chronic Hepatitis B Virus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Chronic Hepatitis B Virus Pipeline Therapeutics Assessment

  • Chronic Hepatitis B Virus Assessment by Product Type
  • Chronic Hepatitis B Virus By Stage and Product Type
  • Chronic Hepatitis B Virus Assessment by Route of Administration
  • Chronic Hepatitis B Virus By Stage and Route of Administration
  • Chronic Hepatitis B Virus Assessment by Molecule Type
  • Chronic Hepatitis B Virus by Stage and Molecule Type

 

DelveInsight’s Chronic Hepatitis B Virus Report covers around 55+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of the key companies in the Chronic Hepatitis B Virus Therapeutics Market include:

Key companies developing therapies for Chronic Hepatitis B Virus are – Gilead Sciences, Dong-A ST Co., Ltd., Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, Vir Biotechnology, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharma, ISA Pharmaceuticals, Dicerna Pharmaceuticals, Yangshengtang Co., Ltd, Altimmune, Hoffmann-La Roche, Fujian Cosunter Pharmaceutical, Precision Biosciences, Beam Therapeutics, SCG Cell Therapy Pte Ltd, Silverback Therapeutics, Bluejay Therapeutics,Indaptus Therapeutics, Immunocore,  and others.

 

Emerging Chronic Hepatitis B Virus Drugs Under Different Phases of Clinical Development Include:

  • PBGENE-HBV: Precision Biosciences
  • SBT8230: Silverback Therapeutics        
  • VIR-3434: Vir Biotechnology
  • AB 729: Arbutus bio
  • RG6346: Dicerna Pharmaceuticals
  • RG7854: Roche
  • Pradefovir: Ligand Pharmaceuticals

 

Get a Free Sample PDF Report to know more about Chronic Hepatitis B Virus Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight

 

Chronic Hepatitis B Virus Pipeline Analysis:

The Chronic Hepatitis B Virus pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Hepatitis B Virus with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Hepatitis B Virus Treatment.
  • Chronic Hepatitis B Virus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Chronic Hepatitis B Virus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Hepatitis B Virus market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Chronic Hepatitis B Virus product details are provided in the report. Download the Chronic Hepatitis B Virus pipeline report to learn more about the emerging Chronic Hepatitis B Virus therapies

 

Chronic Hepatitis B Virus Pipeline Market Drivers

  • High prevalence of chronic HBV infection
  • Increasing Research and development in Chronic Hepatitis B

 

Chronic Hepatitis B Virus Pipeline Market Barriers

  • High cost of treatment
  • Limited access to the diagnosis of hepatitis B

 

Scope of Chronic Hepatitis B Virus Pipeline Drug Insight    

  • Coverage: Global
  • Key Chronic Hepatitis B Virus Companies: Precision Biosciences, Silverback Therapeutics, Vir Biotechnology, Arbutus bio, Dicerna Pharmaceuticals, Roche, Ligand Pharmaceuticals, and others
  • Key Chronic Hepatitis B Virus Therapies: PBGENE-HBV, SBT8230, VIR-3434, AB 729, RG6346, RG7854, Pradefovir, and others
  • Chronic Hepatitis B Virus Therapeutic Assessment: Chronic Hepatitis B Virus current marketed and Chronic Hepatitis B Virus emerging therapies
  • Chronic Hepatitis B Virus Market Dynamics: Chronic Hepatitis B Virus market drivers and Chronic Hepatitis B Virus market barriers 

 

Request for Sample PDF Report for Chronic Hepatitis B Virus Pipeline Assessment and clinical trials

 

Table of Contents

1

Chronic Hepatitis B Virus Report Introduction

2

Chronic Hepatitis B Virus Executive Summary

3

Chronic Hepatitis B Virus Overview

4

Chronic Hepatitis B Virus- Analytical Perspective In-depth Commercial Assessment

5

Chronic Hepatitis B Virus Pipeline Therapeutics

6

Chronic Hepatitis B Virus Late Stage Products (Phase II/III)

7

Chronic Hepatitis B Virus Mid Stage Products (Phase II)

8

Chronic Hepatitis B Virus Early Stage Products (Phase I)

9

Chronic Hepatitis B Virus Preclinical Stage Products

10

Chronic Hepatitis B Virus Therapeutics Assessment

11

Chronic Hepatitis B Virus Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Chronic Hepatitis B Virus Key Companies

14

Chronic Hepatitis B Virus Key Products

15

Chronic Hepatitis B Virus Unmet Needs

16 

Chronic Hepatitis B Virus Market Drivers and Barriers

17

Chronic Hepatitis B Virus Future Perspectives and Conclusion

18

Chronic Hepatitis B Virus Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

Download Sample PDF Report to know more about Chronic Hepatitis B Virus drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/r-and-d-analysis